Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 01, 2026
Nike (NKE) Earnings Preview: Gauging Turnaround Signs After a -40% Slide in 2026

Nike (NKE) Earnings Preview: Gauging Turnaround Signs After a -40% Slide in 2026

Key Takeaways

  • Nike is scheduled to report fiscal first-quarter 2027 results after the market close on Thursday, October 1, for the quarter ended August 31, 2026.
  • Wall Street consensus calls for revenue of roughly $11.3 billion and earnings per share (EPS) of about $0.43 to $0.44, both below the year-ago period.
  • Management has guided for a low-to-mid-single-digit revenue decline for the quarter, with gross margin expected to be only slightly positive.
  • Weakness in Greater China and soft Nike Direct and digital sales remain the biggest watch items heading into the report.
  • Shares are down more than 40% in 2026 and trading near multi-year lows, leaving investor sentiment cautious.

Why This Report Matters for the Turnaround

Nike's fiscal first-quarter update serves as an important checkpoint for the turnaround strategy under CEO Elliott Hill. The company finished fiscal 2026 with essentially flat full-year revenue and a 3% drop in net income, as softer demand in Greater China and a promotional retail environment outweighed pockets of strength in North America and wholesale. I am looking for indications that the "Win Now" plan is stabilizing operations, especially since last quarter's results benefited from a one-time tariff-related item. With the stock near multi-year lows and estimates still being adjusted lower, this release will show whether the cautious guidance and margin recovery story hold up.

To compare NKE with peers in the sector, I also checked this using Tickeron’s AI Screener.

Analyst Forecasts and Guidance

Analysts surveyed by LSEG expect Nike to report adjusted EPS of about $0.43 on revenue of approximately $11.32 billion, according to a CNBC preview. Zacks Consensus Estimates peg revenue near $11.4 billion, implying a year-over-year decline of about 2.7%, and EPS of $0.44, down roughly 10% from $0.49 a year ago. Management has guided for first-quarter revenue to decline in the low-to-mid-single-digit range, with gross margin only slightly positive versus the prior year.

Investors will focus beyond the top-line numbers on Greater China, where sales fell 17% on a constant-currency basis last quarter, as well as Nike Direct and digital trends, which have lagged while wholesale channels stabilized. Inventory levels and the pace of promotional markdowns will also draw attention, along with any updates to full-year fiscal 2027 guidance and the gross-margin recovery timeline.

Investor Sentiment and Recent Stock Performance

Sentiment ahead of the report is cautious. NKE shares have fallen more than 40% in 2026 and trade near levels not seen in over a decade, underperforming a broader market that has advanced this year. In late September, Bank of America downgraded the stock to Underperform and cut its price target to $30 from $47, citing a potentially longer recovery timeline and continued pressure in China. Other firms have trimmed estimates and targets in recent weeks, reflecting weak U.S. footwear demand and caution among retail partners.

Nike has beaten EPS expectations in each of its last four quarters, yet the stock has still struggled, showing how much weight investors place on forward guidance and demand signals over headline beats. A further cut to fiscal 2027 guidance or signs of accelerating China deterioration could renew selling pressure, while any evidence of stabilizing demand or earlier-than-expected margin expansion could provide relief to an oversold stock.

Key Factors to Monitor Ahead

Looking ahead, investors should track whether management reaffirms or adjusts its fiscal 2027 outlook. Management previously signaled that sales were expected to remain "flattish" through the first two quarters, with revenue pressure concentrated in the first half before improving later in the year.

China remains the single largest swing factor. Nike has acknowledged that marketplace cleanup efforts and reduced sell-in will continue to weigh on revenue, and any update on the pace of that reset will shape expectations for the remainder of the fiscal year. Investors will also watch whether Sportswear and Jordan Streetwear show signs of stabilization, given that these categories have been a drag on growth.

Finally, cost and margin trends deserve close attention. The company's gross-margin recovery is expected to begin in the first quarter as it laps prior tariff pressures, but elevated promotions and a planned CFO transition add uncertainty. With an investor day scheduled for November, this earnings report may set the tone for management's longer-term roadmap.

Using AI Tools in My Research Process

I often turn to Tickeron’s AI Screener when preparing for earnings like this one. It lets me quickly filter stocks by technical patterns, fundamentals, and industry trends, helping surface comparable names in consumer goods and footwear far faster than manual checks. The tool has become a regular part of how I assess momentum shifts before reports like Nike’s.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: NKE

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


NKE in -1.93% downward trend, declining for three consecutive days on October 01, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where NKE declined for three days, in 237 of 333 cases, the price declined further within the following month. The odds of a continued downward trend are 71%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Aroon Indicator for NKE entered a downward trend on October 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NKE's RSI Indicator exited the oversold zone, 24 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 59%.

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Moving Average Convergence Divergence (MACD) for NKE just turned positive on September 24, 2026. Looking at past instances where NKE's MACD turned positive, the stock continued to rise in 21 of 43 cases over the following month. The odds of a continued upward trend are 49%.

Following a +1.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where NKE advanced for three days, in 152 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.

NKE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.631) is normal, around the industry mean (2.589). P/E Ratio (17.329) is within average values for comparable stocks, (36.101). Projected Growth (PEG Ratio) (1.427) is also within normal values, averaging (0.949). NKE has a moderately high Dividend Yield (0.045) as compared to the industry average of (0.022). P/S Ratio (1.142) is also within normal values, averaging (1.777).

The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. NKE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 88 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NKE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

Notable companies

The most notable companies in this group are Nike (NYSE:NKE).

Industry description

Companies in this industry handle the wholesale shipments for the manufacturer of a product. They have warehouses and distribution centers, and they ship products directly to the retailer. Digitization, increasing competition, emerging customer demand, and product innovation are some of shifts that the industry has been facing in recent times – something that is potentially creating needs/opportunities for business model revisions or transformations. Data, analytics, and technology are becoming increasingly important for whole distributors in anticipating and analyzing consumer needs, and therefore planning their business strategies accordingly. Fastenal Company, W.W. Grainger, Inc., Genuine Parts Company and Pool Corporation are some of the largest names in the business.

Market Cap

The average market capitalization across the Wholesale Distributors Industry is 6.65B. The market cap for tickers in the group ranges from 22K to 53.98B. NKE holds the highest valuation in this group at 53.98B. The lowest valued company is JALA at 22K.

High and low price notable news

The average weekly price growth across all stocks in the Wholesale Distributors Industry was 2%. For the same Industry, the average monthly price growth was 10%, and the average quarterly price growth was 18%. VRA experienced the highest price growth at 22%, while FMFC experienced the biggest fall at -11%.

Volume

The average weekly volume growth across all stocks in the Wholesale Distributors Industry was 68%. For the same stocks of the Industry, the average monthly volume growth was 168% and the average quarterly volume growth was 24%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 39
P/E Growth Rating: 73
Price Growth Rating: 51
SMR Rating: 62
Profit Risk Rating: 89
Seasonality Score: 34 (-100 ... +100)
View a ticker or compare two or three
NKE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a maker of athletic footwear and apparel

Industry WholesaleDistributors

Industry
Apparel Or Footwear
Address
One Bowerman Drive
Phone
+1 503 671-6453
Employees
73000
Web
https://www.nike.com
Interact to see
Advertisement
MRSH stock declined approximately -9% over the past 30 days, driven by sector-wide AI disruption fears and analyst downgrades. Over the past quarter, the stock fell around -7%, amid softening insurance rates and declining fiduciary interest income.
MCO stock declined approximately -9% over the last 30 days amid profit-taking, insider selling, and sector-wide concerns in financial data analytics. Over the past quarter, shares fell around -18%, reflecting a correction from January highs despite strong Q4 2025 earnings. Key drivers include post-earnings selloff after Q4 results, analyst price target cuts, and broader market volatility in credit ratings sector.
SNOW stock declined approximately -9% over the last 30 days, from around $168 to $153, amid post-earnings profit-taking and analyst caution despite strong results. Over the past quarter, the stock fell about -31%, from near $223, reflecting broader sector pressures and valuation concerns in cloud software.
WDS stock surged +24% over the past 30 days, driven by a sharp rally in oil and LNG prices amid Middle East supply disruptions, including Strait of Hormuz issues and strikes on Qatar's Ras Laffan facility. Over the past quarter, the stock climbed +55%, reflecting sustained energy market volatility and Woodside's strong production from assets like Sangomar and Pluto LNG.
HMC stock declined -19% over the past 30 days amid major setbacks in EV strategy, including cancellation of North American EV models and up to $15.7 billion in related losses. Over the past quarter, shares fell -18%, driven by persistent auto segment weakness, tariff impacts, and revised FY2026 forecasts to a net loss. Key catalysts include March EV reassessment announcement causing a 5%+ drop, Q3 earnings beat overshadowed by one-time charges and guidance concerns, and Sony-Honda JV EV project halt.
EL stock plunged approximately -39% over the past 30 days amid merger discussions with Puig, tariff pressures, and restructuring costs, marking a highly volatile period. Over the past quarter, the stock is down around -37%, reflecting broader sector headwinds despite earlier quarterly earnings beats. Key drivers include confirmation of potential business combination with Puig sparking uncertainty, ongoing $100 million tariff impacts, and elevated restructuring expenses.
ESLT stock rose +13% over the past 30 days, driven primarily by a blowout Q4 2025 earnings report with revenue up 11% and EPS beating estimates by over 10%. Over the past quarter, shares surged +52%, fueled by a record $28.1 billion order backlog, up significantly year-over-year, amid heightened global defense demand. Geopolitical tensions in the Middle East boosted demand for Elbit's systems, alongside major contract wins totaling hundreds of millions from international clients.
EQT stock rose approximately +10% over the last 30 days, driven by strong Q4 2025 earnings beat, robust free cash flow guidance for 2026, and analyst price target increases. Over the past quarter, shares gained around +23%, fueled by operational efficiencies, natural gas price recovery, and positive sector sentiment amid LNG demand growth.
Robin Energy Ltd is a Cyprus-based shipping company focused on ocean and deep-sea freight transportation. As a holding entity, it acquires, owns, charters, and manages oceangoing tanker vessels worldwide. The core of its business lies in energy transportation services, mainly through handysize tankers and LPG carriers. In the competitive marine shipping industry, RBNE positions itself as a growth-oriented player, expanding its fleet and locking in multi-year charters. Recent developments, such as vessel acquisitions and Bitcoin treasury allocations, leave it exposed to shipping cycles and alternative asset volatility. From what I see, this mix contributes to the erratic stock price behavior we've observed amid shifting global energy demand and freight rates.
NG stock plunged -42% over the past 30 days amid sharp declines from mid-March peaks around $14, driven by profit-taking after a multi-year rally and sector-wide weakness in gold mining stocks. Over the past quarter, the stock is down -14%, reflecting volatility from early-year gains tied to financing successes offset by recent macro pressures and permitting concerns. Key drivers include gold price fluctuations due to interest rate expectations, profit-taking post-240%+ annual surge, and no immediate production revenue despite Donlin Gold project advancements.
CRBU stock declined approximately -10% over the past 30 days, reflecting volatility amid clinical updates and financing concerns. Over the past quarter, the stock rose about +12%, driven by positive earnings beats and pipeline progress. Key drivers include Q4 2025 earnings beat, vispa-cel Phase 3 plans, but offset by cash burn and need for additional capital.
Shares of Viridian Therapeutics (VRDN) are down approximately 32% in premarket trading on March 30, 2026, against a prior closing price of $27.39 on March 27, 2026, implying a premarket price near $18.63. The primary catalyst is the release of topline Phase 3 REVEAL-1 clinical trial data for elegrobart (VRDN-003) in patients with active thyroid eye disease (TED), long anticipated as the company's most critical near-term de-risking event.
SYY shares are trading approximately -6.40% lower in premarket trading on March 30, 2026, from a prior close of $81.80 to roughly $76.56. The primary catalyst is Sysco's announcement of a $29.1 billion definitive agreement to acquire Jetro Restaurant Depot, one of the nation's largest Cash & Carry food wholesalers.
Northwest Biotherapeutics, Inc. (NWBO) is a clinical-stage biotechnology company focused on developing personalized immune therapies, primarily dendritic cell-based vaccines under its DCVax platform. The company's lead candidate, DCVax-L, targets glioblastoma multiforme (GBM), a lethal brain cancer, following completion of a Phase III trial. DCVax-Direct addresses inoperable solid tumors, with Phase I/II data available. NWBO operates in the competitive immunotherapy sector against players like large-cap biotechs, relying on a proprietary manufacturing process for cost-effective production.
FingerMotion, Inc. (FNGR) operates as a mobile data specialist, delivering mobile payment and recharge platform solutions mainly in China. The company's core revolves around telecommunication products and services, such as top-up recharges, data plans, SMS and MMS services, big data insights for consumer behavior analysis, and rich communication services (RCS) platforms. It also provides value-added products through partnerships with telecom providers and e-commerce platforms.
NIO Inc. (NIO) stands out as a leading Chinese electric vehicle manufacturer focused on premium smart EVs. The company designs, develops, and sells high-end battery electric vehicles, bolstered by its Battery-as-a-Service model that lets customers swap batteries at stations rather than owning them. In the cutthroat Chinese EV space, NIO competes directly with firms like XPEV and LI.
Xcel Energy Inc. (XEL) stands out as a major U.S. electric and natural gas utility, serving about 3.7 million electric and 2.2 million natural gas customers across eight states, mainly in the Midwest and West. The company focuses on regulated utilities, handling electricity generation, transmission, and distribution, while increasingly prioritizing renewable sources like wind and solar. Its model centers on steady, regulated returns from infrastructure investments, backed by rate cases and recovery mechanisms.
Occidental Petroleum Corporation (OXY) stands out as a leading independent energy producer, with a primary focus on hydrocarbon exploration and production. The company has significant operations in the Permian Basin, one of the U.S.'s most productive oil regions, along with assets in the Rockies, Latin America, and the Middle East. Its business model emphasizes efficient drilling, low-cost production, and carbon capture initiatives aimed at long-term sustainability.
The ProShares UltraShort Bloomberg Natural Gas (KOLD) is a leveraged inverse exchange-traded fund that seeks daily investment results, before fees and expenses, corresponding to two times the inverse (-2x) of the daily performance of the Bloomberg Natural Gas Subindex. This subindex reflects the natural gas segment of the commodities market by tracking futures contracts, primarily the second-month Henry Hub natural gas futures, weighted by liquidity and production. The fund does not invest directly in physical natural gas but uses derivatives like futures contracts and swaps to achieve its objective.
Shares of United Therapeutics (UTHR) are surging approximately +17% in premarket trading on Monday, March 30, 2026, with the market not yet open. The primary catalyst is a landmark Phase 3 clinical trial announcement: the TETON-1 pivotal study of nebulized Tyvaso® (treprostinil) met its primary endpoint for treating idiopathic pulmonary fibrosis (IPF), exceeding the already impressive treatment effects seen in the previously completed TETON-2 study.